VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
VAXCYTE, INC. (PCVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.30% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-05
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.30%, a 2.38% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.80%, a 15.56% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 3.90%, a 11.36% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.20%, a 6.67% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.60%, a 4.55% increase from fiscal 2022.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.40%, a 238.46% increase from fiscal 2021.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.30%, a 7.14% decline from fiscal 2020.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.40%, a 41.67% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-05 | 4.30% 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 3.80% 10-Q · filed 2026-05-06 | |||
| 2025-09-30 | 3.90% 10-Q · filed 2025-11-04 | 4.50% 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | 4.20% 10-Q · filed 2026-08-05 | 4.50% 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-06 | |||
| 2024-09-30 | 4.40% 10-Q · filed 2025-11-04 | 4.50% 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-06 | 4.50% 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 4.60% 10-K · filed 2024-02-27 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2024-11-05 | 4.40% 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | 4.00% 10-Q · filed 2024-08-06 | 4.30% 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | 4.30% 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 4.40% 10-K · filed 2024-02-27 | |||
| 2022-09-30 | 4.00% 10-Q · filed 2023-11-06 | 4.00% 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-08 | 3.00% 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | 2.40% 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 1.30% 10-K · filed 2024-02-27 | |||
| 2021-09-30 | 1.10% 10-Q · filed 2022-11-07 | 1.10% 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | 1.00% 10-Q · filed 2022-08-08 | 1.00% 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | 1.00% 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | 1.40% 10-K · filed 2023-02-27 | |||
| 2020-09-30 | 1.40% 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 1.40% 10-Q · filed 2021-08-11 | |||
| 2019-12-31 | 2.40% 10-K · filed 2022-02-28 | |||
| 2019-09-30 | 1.80% 10-Q · filed 2020-11-12 | 2.40% 10-Q · filed 2020-11-12 | ||
| 2018-12-31 | 2.90% 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |